Category Archives: Washington

California Legislators Hold Key Leadership and Committee Positions in Congress

With the opening of the 116th Congress, California’s congressional delegation in the House of Representatives continues to rank amongst the most influential, with numerous members serving in positions of leadership and on committees with jurisdiction over issues and policies critical to the continued advancement of our state’s and the nation’s life sciences sector. Notably, California’s 46 Democratic members comprise 20% of all House Democrats – the current majority party.

New Legislator Spotlight: Congressman Gil Cisneros (D–Yorba Linda)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Gil Cisneros (D–Yorba Linda). We look forward to working with Rep. Cisneros and his team to advance policies that improve patient health and bring positive change for California patients and their families.

CLSA Hosts Meet & Greet with Congressman-elect Mike Levin (CA-49)

By Jenny Nieto Nov. 16, 2018 On Nov. 16, CLSA was honored to convene a Meet & Greet with Representative-elect Mike Levin (D-San Juan Capistrano/San Diego) at our Washington, DC office. As you may know, attorney Mike Levin was elected Nov. 6  to serve as the new U.S. Representative for California’s 49th Congressional District.  He … Continue reading CLSA Hosts Meet & Greet with Congressman-elect Mike Levin (CA-49)

2018 Federal Midterms Election Roundup

CLSA’s federal government relations team is pleased to provide you with this update on the 2018 Midterm Elections, including the likely makeup of our incoming California delegation for the 116th Congress, and additional details on several key California congressional races you may be interested in.

Trump Administration Advancing Proposals Outlined in “Blueprint” to Address Prescription Drug Pricing

Addressing drug pricing and improving healthcare access and affordability remains a salient topic on Capitol Hill, in the Trump Administration, with industry and the public. Over the summer, the Administration released its American Patients First blueprint, and over the past several weeks, the Administration has announced draft or final proposals intended to lower drug prices and increase access to affordable prescription drugs.

What’s Next for the Remainder of 2018? Federal Legislative Outlook on Government Funding, Medical Device Tax and PAHPA Reauthorization

Both the House and Senate have adjourned until after the midterm elections. While the outcome of the elections will determine whether the Democrats win a majority in either the House or the Senate (or both), or if the Republicans maintain control of one or both chambers in the 116th Congress, both the House and Senate will return to Washington, D.C. in late November and early December (approximately 16-20 legislative days) to finish legislative work prior to the end of the year and the 115th Congress.